2. (Amended) A method of inducing immunotolerance in a patient having a transplanted organ, tissue, cell, or the like comprising administering an effective amount of a humanized immunoglobulin having binding specificity for B7-2, said immunoglobulin comprising:

a) at least one antigen binding region of nonhuman origin, and

b) at least a portion of an immunoglobulin of human origin derived from the III2R and/or the H2F antibody,

wherein the immunoglobulin is administered in a carrier, and wherein the humanized has a binding affinity of at least about 10^7 M^{-1}.

3. (Amended) A method of reducing transplantation rejection in a patient having a transplanted organ, tissue, or cell, comprising administering a therapeutically effective amount of a humanized antibody having binding specificity for B7-2, said immunoglobulin comprising:

a) at least one antigen binding region of nonhuman origin, and

b) at least a portion of an immunoglobulin of human origin derived from the III2R and/or the H2F antibody,

wherein the humanized immunoglobulin has a binding affinity of at least about 10^7 M^{-1}.

Please add new claims as follows:

6. (New) The method of claim 1, wherein said at least one antigen binding region further comprises at least one CDR of the 3D1 antibody.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

7. (New) The method of claim 1, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

8. (New) The method of claim 7, wherein said immunoglobulin further comprises a constant region comprising a human IgG4 isotype.

9. (New) The method of claim 7, wherein said immunoglobulin further comprises a constant region comprising a human IgG2M3 isotype.

10. (New) The method of claim 1, wherein said portion of an immunoglobulin of human origin is derived at least from the human antibody III2R heavy chain.

11. (New) The method of claim 1, wherein said portion of an immunoglobulin of human origin is derived at least from the human antibody H2F light chain.

12. (New) The method of claim 2, wherein said at least one antigen binding region further comprises at least one CDR of the 3D1 antibody.

13. (New) The method of claim 2, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

14. (New) The method of claim 13, wherein said immunoglobulin further comprises a constant region comprising a human IgG4 isotype.

15. (New) The method of claim 13, wherein said immunoglobulin further comprises a constant region comprising a human IgG2M3 isotype.

16. (New) The method of claim 2, wherein said portion of an immunoglobulin of human origin is derived at least from the human antibody III2R heavy chain.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

17. (New) The method of claim 2, wherein said portion of an immunoglobulin of human origin is derived at least from the human antibody H2F light chain.

18. (New) The method of claim 3, wherein said at least one antigen binding region further comprises at least one CDR of the 3D1 antibody.

19. (New) The method of claim 3, wherein said immunoglobulin comprises a light chain encoded by the amino acid sequence of SEQ ID NO: 8 and a heavy chain encoded by the amino acid sequence of SEQ ID NO: 6.

20. (New) The method of claim 19, wherein said immunoglobulin further comprises a constant region comprises a human IgG4 isotype.

21. (New) The method of claim 19, wherein said immunoglobulin further comprises a constant region comprises a human IgG2M3 isotype.

22. (New) The method of claim 3, wherein said portion of an immunoglobulin of human origin is derived at least from the human antibody III2R heavy chain.

23. (New) The method of claim 3, wherein said portion of an immunoglobulin of human origin is derived at least from the human antibody H2F light chain.

24. (New) The method of claim 1, wherein the binding affinity is about $10^9\ M^{-1}$.

25. (New) The method of claim 2, wherein the binding affinity is about $10^9\ M^{-1}$.

26. (New) The method of claim 3, wherein the binding affinity is about $10^9\ M^{-1}$.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com